GSK Reports the P-III (GLISTEN) Study Results of Linerixibat to Treat Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus
Shots:
- The P-III (GLISTEN) study assessed the safety & efficacy of linerixibat vs PBO to treat primary biliary cholangitis patients with cholestatic pruritus
- Study achieved its 1EP, demonstrating significantly reduced itch in PBC patients, as assessed by monthly itch score, over 24wks, with safety results aligning with previous studies. Further data analysis is underway
- Linerixibat, an IBAT inhibitor, targets cholestatic pruritus in PBC by blocking bile acid re-uptake. It has received ODD from the US FDA and EMA for the same
Ref: GSK | Image: GSK
Related News:- GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
